Menu
Search
|

Menu

Close
X

Sierra Oncology Inc SRRA.OQ (NASDAQ Stock Exchange Global Market)

2.90 USD
-0.06 (-2.03%)
As of Feb 16
chart
Previous Close 2.96
Open 2.97
Volume 39,399
3m Avg Volume 105,196
Today’s High 3.03
Today’s Low 2.87
52 Week High 4.09
52 Week Low 1.11
Shares Outstanding (mil) 52.30
Market Capitalization (mil) 151.66
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.33 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-0.649
FY16
-1.583
FY15
-115.639
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.43
Price to Sales (TTM)
vs sector
--
8.57
Price to Book (MRQ)
vs sector
1.46
5.14
Price to Cash Flow (TTM)
vs sector
--
25.75
Total Debt to Equity (MRQ)
vs sector
0.00
15.12
LT Debt to Equity (MRQ)
vs sector
0.00
11.85
Return on Investment (TTM)
vs sector
-37.88
13.54
Return on Equity (TTM)
vs sector
-37.88
14.80

EXECUTIVE LEADERSHIP

Donald Parfet
Independent Chairman of the Board, Since 2003
Salary: --
Bonus: --
Nicholas Glover
President, Chief Executive Officer, Director, Since 2014
Salary: $525,000.00
Bonus: --
Sukhi Jagpal
Chief Financial Officer, Since 2015
Salary: --
Bonus: --
Barbara Klencke
Chief Development Officer, Since 2015
Salary: $420,000.00
Bonus: --
Mark Kowalski
Chief Medical Officer, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

2150-885 Georgia St W
VANCOUVER   BC   V6C 3E8

Phone: +1604.5586536

Sierra Oncology, Inc., formerly ProNAi Therapeutics, Inc., is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network. SRA737 is being investigated in approximately two Phase I clinical trials in patients with advanced cancer. Sierra Oncology is also advancing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase (Cdc7) kinase undergoing preclinical development. Sierra is building a range of pipeline of various oncology assets against targets at the edge of cancer biology. The Company’s SRA737 and SRA141 target the DDR network, a scientifically approach with far-reaching potential across oncology. SRA141 is an orally available small molecule inhibitor of Cdc7.

SPONSORED STORIES